|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Chronic Obstructive Pulmonary Disease Drug Pipeline Report
Detailed information on the current drug pipeline. This report provides insight into the pipeline status of chronic obstructive pulmonary disease drugs by company and by stage as well as a summary of the latest news and developments in this area.
Respiratory Market Insight 2008
This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies.
Forecast Insight: Asthma/COPD
In-depth overview and ten year outlook for currently marketed respiratory drugs, focussing on the Asthma and COPD indications, examining both clinical and commercial factors driving product differentiation and uptake.
Respiratory Handbook 2005-15:Novartis Moving Into the Major
The respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets. Future growth will be essentially flat over the next 10 years (CAGR, 0.6%), estimated to
Respiratory Key Players - GSK Blows Away the Opposition
The large and growing size of the respiratory market, both in terms of patients and current global spend, has encouraged a number of companies to try to enter the sector, as current players attempt to strengthen their portfolios. The top ten companies
Stakeholder Perspectives: Pulmonary Arterial Hypertension
Datamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this i
Advanced Life Sciences Cethromycin - Phase III success...
Traditionally, the treatment of respiratory infections has largely involved antibiotics from the macrolide class. Advanced Life Sciences’ cethromycin, along with Sanofi-Aventis’ Ketek, is a ketolide, a second-generation class of macrolides
Stakeholder Insight: Respiratory Tract Infections
In the US, approximately 88 million people are diagnosed with a respiratory tract infection in an average year. Of these, a total of 66 million patients suffer from one of the three major diagnoses: acute bacterial sinusitis (ABS), acute exacerbation
Stakeholder Opinions: Respiratory Syncytial Virus
RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly
Results 1 - 19 of 19
|
|
|
|
